Available in Chile, United States
The duration of the study for a participant will include:
Screening Period: up to 28 days Treatment Period: enrolled and exposed participants will
receive continuous treatment until progressive disease (PD), or an occurrence of an
unacceptable AE, a withdrawal of consent, or until other permanent discontinuation
criteria described in the protocol are met.
The End of Treatment (EOT) visit will occur 30 days ±7 days from the last IMP
administration or prior to the initiation of further therapy, whichever occurs first.
The follow-up period will occur until disease progression, the start of new anticancer
therapy, death, or withdrawal of participant's consent, whichever comes first.
1Research sites
291Patients around the world